Intervacc is trading 15.01% down at €0.08 after no confirmed company-specific catalyst was identified on August 17, 2026, and the reason for the decline remains unclear. - The latest notable development was its July 30 EMA application seeking 12-month Strangvac immunity. - Second-quarter results are scheduled for August 20; broader market indices were essentially unchanged.